Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 5;2(6):395-401.
doi: 10.1002/bco2.111. eCollection 2021 Nov.

Transperineal prostate biopsy identifies locations of clinically significant prostate cancer in men considering focal therapy with PI-RADS 3-5 regions of interest

Affiliations

Transperineal prostate biopsy identifies locations of clinically significant prostate cancer in men considering focal therapy with PI-RADS 3-5 regions of interest

Nelson Stone et al. BJUI Compass. .

Abstract

Objectives: To determine the benefit of performing transperineal prostate mapping biopsy (TPMB) following multiparametric magnetic resonance imaging (mpMRI) to increase the identification of clinically significant prostate cancer (csPCa) with Gleason grade group (GG) ≥ 2 and their locations outside of the PI-RADS v2 3-5 category lesions.

Methods: mpMRI was performed in 80 men prior TPMB from two institutions. The mpMRI was considered clinically significant (csMRI) if it contained one or more PI-RADS 3-5 category lesion. mpMRI findings were compared against csPCa diagnosed by TPMB, performed between 16 November 2010, and 13 September 2019, for the entire gland, both lobes and to the right and left anterior and right and left posterior quadrants (RA, LA, RP and LP). Sensitivity, specificity, positive and negative predictive values (PPV, NPV), accuracy and the area under curve (AUC) were determined. Thirteen men also underwent radical prostatectomy and had comparison of TPMB pathology to prostatectomy specimen grading.

Results: TPMB was positive in 60/80 (75%) of which 32 (53.3%) were csPCa. csPCa was present in the RA in 9 (11.3%), LA in 11 (13.8%), RP in 25 (31.3%) and LP in 27 (33.8%) and involved 1 quadrant in 7 (21.9%), 2 quadrants in 12 (37.5%), 3 quadrants in 11 (34.4%) and all 4 quadrants in 2 (6.3%) patients; 57/80 (71.3%) men had a mpMRIs with lesions designated as PI-RADS 3 in 24 (30%), 4 in 25 (31.3%) and 5 in 8 (10%). A csMRI was present in the RA in 7 (8.8%), LA in 8 (10%), RP in 31 (38.8%) and in the LP in 29 (36.3%), which were limited to one quadrant in 39 (68.4%), 2 quadrants in 16 (28.1%), and 3 quadrants in 2 (3.5%). Sensitivity, specificity, PPV, and NPV were determined from the results of the TPMB and were for the entire gland 81.3%, 35.4%, 45.6% and 73.9%. There were 31 csMRIs involving the right posterior of the gland but only 25 csPCa by TPMB of which 12/31 (38.7%) were concordant for high grade disease. There were 29 men who have a csMRI in the left posterior quadrant, and 14 (48.3%) were concordant with csPCa from the TPMB.

Conclusions: MpMRI should be supplemented with TPMB to correctly identify the regions of the prostate that would require ablation in men considering focal therapy.

Keywords: mpMRI; prostate biopsy; transperineal mapping.

PubMed Disclaimer

Conflict of interest statement

N. N. Stone and M. S. Lucia have ownerships in Triopsy, Inc. There was no financial assistance from Triopsy in this investigation or in the production of the manuscript.

Figures

FIGURE 1
FIGURE 1
(A) T2 sequence of multiparametric magnetic resonance imaging (mpMRI) with prostate divided into 4 sectors with urethra (green circle) as axis. Region circled in yellow represents PI‐RADs 4 lesion. (B) Four sectors (quadrants) from axial ultrasound prostate image. Red line represents circumference of prostate and green circle urethra. Green dots are template puncture sites. RA—right anterior, LA—left anterior, RP—right posterior, LP—left posterior. Proprietary software programme not available for clinical use

Similar articles

Cited by

References

    1. Patel NU, Lind KE, Garg K, Crawford D, Werahera PN, Pokharel SS. Assessment of PI‐RADS v2 categories >/= 3 for diagnosis of clinically significant prostate cancer. Abdom Radiol. 2019;44:705–12. - PubMed
    1. Sathianathen NJ, Omer A, Harriss E, Davies L, Kasivisvanathan V, Punwani S, et al. Negative predictive value of multiparametric magnetic resonance imaging in the detection of clinically significant prostate Cancer in the prostate imaging reporting and data system era: a systematic review and Meta‐analysis. Eur Urol. 2020;78:402–14. - PubMed
    1. Johnson DC, Yang JJ, Kwan L, Barsa DE, Mirak SA, Pooli A, et al. Do contemporary imaging and biopsy techniques reliably identify unilateral prostate cancer? Implications for hemiablation patient selection. Cancer. 2019;125:2955–64. - PMC - PubMed
    1. Crawford ED, Rove KO, Barqawi AB, Maroni PD, Werahera PN, Baer CA, et al. Clinical‐pathologic correlation between transperineal mapping biopsies of the prostate and three‐dimensional reconstruction of prostatectomy specimens. Prostate. 2013;73:778–87. - PMC - PubMed
    1. Jain AL, Sidana A, Maruf M, Sugano D, Calio B, Wood BJ, et al. Analyzing the current practice patterns and views among urologists regarding focal therapy for prostate cancer. Urol Oncol. 2019;37:e1–8. - PMC - PubMed

LinkOut - more resources